Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

KDMN / Kadmon Holdings, Inc. 8-K (Current Report)

2018-02-23 sec.gov
8K - cGVHD  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K    CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  February 22, 2018     Kadmon Holdings, Inc. (Exact name of registrant as specified in its charter)                        Delaware   001-37841   27-3576929 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. (27-0)

Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD | Business Wire

2018-02-23 businesswire
NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated positive results from an ongoing Phase 2 clinical trial (KD025-208) evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with chronic graft-versus-host disease (cGVHD). The results are being presented today in an oral presentation at the BMT Tandem Meetings in Salt Lake City. (27-0)

Tracking Dan Loeb's Third Point Portfolio - Q4 2017 Update

2018-02-22 seekingalpha
Dan Loeb's 13F portfolio value increased from $11.90B to $13.86B this quarter. The number of positions increased from 37 to 44. (974-6)

KDMN / Kadmon Holdings, Inc. / RA Capital Management, LLC - SC 13G (Passive Investment)

2018-02-16 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934   (Amendment No. ___)*   Kadmon Holdings, Inc.   (Name of Issuer)   Common Stock, par value $0.001 per share   (Title of Class of Securities)   48283N106   (CUSIP Number)   December 31, 2017   (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) ¨ Rule 1

KDMN / Kadmon Holdings, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G (Passive Investment)

2018-02-16 sec.gov
Amendment No. 1 to Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Kadmon Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 48283N 10 6 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Ru

KDMN / Kadmon Holdings, Inc. / RA Capital Management, LLC - SC 13G (Passive Investment)

2018-02-15 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934   (Amendment No. ___)*   Kadmon Holdings, Inc.   (Name of Issuer)   Common Stock, par value $0.001 per share   (Title of Class of Securities)   48283N106   (CUSIP Number)   December 31, 2017   (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) ¨ Rule 1

KDMN / Kadmon Holdings, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G (Passive Investment)

2018-02-15 sec.gov
Amendment No. 1 to Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Kadmon Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 48283N 10 6 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Ru

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

2018-02-15 seekingalpha
Today we will focus on Achaogen (AKAO), which got a slight boost after Tetraphase Pharma’s (TTPH) drug failed to beat ertapenem in a late-stage cUTI study. (426-3)

KDMN / Kadmon Holdings, Inc. / ACUTA CAPITAL PARTNERS, LLC - 3G (Passive Investment)

2018-02-14 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. ______)*   KADMON HOLDINGS, INC. (Name of Issuer)   COMMON STOCK (Title of Class of Securities)   48283N106 (CUSIP Number)   ACUTA CAPITAL PARTNERS LLC, 1301 SHOREWAY ROAD, SUITE 350, BELMONT CA 94002 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)   December 31, 2017 (Date of Event which Requires F

KDMN / Kadmon Holdings, Inc. / ACUTA CAPITAL PARTNERS, LLC - 3G (Passive Investment)

2018-02-14 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. ______)*   KADMON HOLDINGS, INC. (Name of Issuer)   COMMON STOCK (Title of Class of Securities)   48283N106 (CUSIP Number)   ACUTA CAPITAL PARTNERS LLC, 1301 SHOREWAY ROAD, SUITE 350, BELMONT CA 94002 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)   December 31, 2017 (Date of Event which Requires F

U.S. Biotech/Pharma Sector Daily Observations Letter: February 12, 2018

2018-02-13 seekingalpha
The broad U.S. equities sector and the biotech sector rebounded today as we mentioned last week and then pulled back towards the end of the day. After a small pullback, the uptrend could likely resume in a day or so. Whether we will make new highs or go to new lows is unclear, but we are in favor of new lows (breaking Friday lows) and then new highs to end the 2009-2018 bull market (over next 6-9 months). (27-0)

KDMN / Kadmon Holdings, Inc. 8-K (Current Report)

2018-02-12 sec.gov
8K - IPF  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K    CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  February 12, 2018     Kadmon Holdings, Inc. (Exact name of registrant as specified in its charter)                        Delaware   001-37841   27-3576929 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

KDMN / Kadmon Holdings, Inc. ESP

2018-02-10 sec.gov
Acceleration Request   Kadmon Holdings, Inc.  450 East 29th Street New York, NY 10016   January 8, 2018   VIA FACSIMILE AND EDGAR TRANSMISSION   U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-0404        Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance    Re: Kadmon Holdings, Inc.  Registration Statement on Form S-3  Filed December 29, 2017  File No.

KDMN / Kadmon Holdings, Inc. ER

2018-02-10 sec.gov
January 8, 2018 Harlan Waksal President and Chief Executive Officer Kadmon Holdings, Inc. 450 East 29th Street New York, NY 10016 Kadmon Holdings, Inc. Registration Statement on Form S-3 Filed December 29, 2017 File No. 333-222364 Re: Dear Dr. Waksal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.

KDMN / Kadmon Holdings, Inc. / Third Point LLC - SCHEDULE 13G/A, 1 (Passive Investment)

2018-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kadmon Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 48283N106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder o


CUSIP: 48283N106